Key result
Human monocyte and macrophage cell assays enable targeted screening for atherosclerosis immunopathology and immune therapies.
Answers are grounded in this paper and cite their sources.
Immunopathology plays important roles in the development of different life-threatening diseases, such as atherosclerosis and its consequences (acute myocardial infarction and stroke), cancer, chronic inflammatory diseases. Effective modulation of the immune system may significantly increase the efficacy of prevention and therapy efforts. Currently there are no marketed drugs capable of normalizing immune system function in an intrinsic and comprehensive way. Here, we describe a test system designed for complex analysis of monocyte activity in individuals to diagnose immunopathology and monitor treatment efficacy. This cell-based test system may also be useful for screening compounds with an immune-correcting effects. Both diagnostic and screening systems are based on primary culture of human monocytes and/or monocyte-derived macrophages. This is the first step in creating a method for assessment of macrophage activity, which is required for further development of immune-correcting drugs. The existing preliminary data provide the basis for realization of this idea.
No takes yet. Share an insight, caveat, or question.
Orekhov et al. (2014) conducted a review in Atherosclerosis and immunopathology. Cell-based test system using primary culture of human monocytes and monocyte-derived macrophages was evaluated on Assessment of monocyte and macrophage activity. A primary human monocyte and macrophage cell-based test system is proposed to diagnose immunopathology in atherosclerosis and screen immune-correcting drugs (no quantitative results reported).
Synapse has enriched 10 related papers. Consider them for comparative context: